Besides, as only less than half dMMR CRC patients benefit from anti-PD-1 therapy, MMR status might not be the only positive predictor for anti-PD-1 therapy, some other predictive indexes should be explored to combine with MMR status in order to better predict the curative effect. The gene discussed is MRC1; the disease is colorectal carcinoma.